| Citation: |
TIAN Zhuang, ZHANG Shuyang. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 801-806. DOI: 10.12290/xhyxzz.2024-0292
|
In the past few years, there have been many breakthroughs in the treatment of heart failure, especially in drug therapy. The classification of chronic heart failure and treatment methods for heart failure and its complications are also constantly updated. In order to apply these achievements to a better diagnosis and treatment of heart failure patients in China, Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology have jointly published the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024, which comprehensively updates the new consensus and evidence-based treatment in the field of heart failure. These contents are of great significance for guiding diagnosis and treatment of heart failure patients in clinical practice. This article, therefore, aims to interpret the main updated contents and key points to provide readers with a better understanding of its key information.
| [1] |
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018[J]. Chin J Cardiol, 2018, 46(10): 760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004
|
| [2] |
中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202404009.htm
Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, Chinese Heart Failure Association of Chinese Medical Doctor Association, et al. Chinese guidelines for the diagnosis and treatment of heart failure 2024[J]. Chin J Cardiol, 2024, 52(3): 235-275. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202404009.htm
|
| [3] |
Halliday B P, Wassall R, Lota A S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy(TRED-HF): an open-label, pilot, randomised trial[J]. Lancet, 2019, 393(10166): 61-73. DOI: 10.1016/S0140-6736(18)32484-X
|
| [4] |
McMurray J J V, Solomon S D, Inzucchi S E, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. DOI: 10.1056/NEJMoa1911303
|
| [5] |
Packer M, Anker S D, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424. DOI: 10.1056/NEJMoa2022190
|
| [6] |
Armstrong P W, Pieske B, Anstrom K J, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20): 1883-1893. DOI: 10.1056/NEJMoa1915928
|
| [7] |
McDonagh T A, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur J Heart Fail, 2022, 24(1): 3599-3726.
|
| [8] |
Heidenreich P A, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e895-e1032.
|
| [9] |
McMurray J J V, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine[J]. Circulation, 2021, 143(9): 875-877. DOI: 10.1161/CIRCULATIONAHA.120.052926
|
| [10] |
Hulot J S, Trochu J N, Donal E, et al. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging thera-peutic options[J]. Expert Opin Pharmacother, 2021, 22(14): 1847-1855. DOI: 10.1080/14656566.2021.1937121
|
| [11] |
Greene S J, Ezekowitz J A, Anstrom K J, et al. Medical therapy during hospitalization for heart failure with reduced ejection fraction: the VICTORIA registry[J]. J Card Fail, 2022, 28(7): 1063-1077. DOI: 10.1016/j.cardfail.2022.02.011
|
| [12] |
Anker S D, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med, 2021, 385(16): 1451-1461. DOI: 10.1056/NEJMoa2107038
|
| [13] |
Solomon S D, McMurray J J V, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022, 387(12): 1089-1098. DOI: 10.1056/NEJMoa2206286
|
| [14] |
中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYX202310002.htm
Chinese Society of Cardiology, Chinese Medical Association, Heart Rhythm Committee of Chinese Society of Biomedical Engineering. Chinese guidelines on diagnosis and manage-ment of atrial fibrillation[J]. Chin J Cardiol, 2023, 51(6): 572-618. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYX202310002.htm
|
| [15] |
Sohns C, Fox H, Marrouche N F, et al. Catheter ablation in end-stage heart failure with atrial fibrillation[J]. N Engl J Med, 2023, 389(15): 1380-1389.
|
| [16] |
Ponikowski P, Kirwan B A, Anker S D, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial[J]. Lancet, 2020, 396(10266): 1895-1904.
|
| [17] |
Kalra P R, Cleland J G F, Petrie M C, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK(IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial[J]. Lancet, 2022, 400(10369): 2199-2209.
|
| [18] |
Anker S D, Khan M S, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis[J]. Eur J Heart Fail, 2023, 25(7): 1080-1090.
|
| [19] |
McDonagh T A, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639.
|
| [20] |
Mentz R J, Garg J, Rockhold F W, et al. Ferric carboxymaltose in heart failure with iron deficiency[J]. N Engl J Med, 2023, 389(11): 975-986.
|
| [21] |
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocar-dial and Pericardial Diseases[J]. Eur J Heart Fail, 2021, 23(4): 512-526.
|
| [22] |
田庄, 张抒扬. 《转甲状腺素蛋白心脏淀粉样变诊断与治疗中国专家共识》解读及诊断路径更新[J]. 罕见病研究, 2023, 2(1): 63-69. https://www.cnki.com.cn/Article/CJFDTOTAL-HJBI202301009.htm
Tian Z, Zhang S Y. The interpretation and update of the diagnosis pathway of Chinese expert consensus on the diagnosis and treatment of transthyretin cardiac amyoidosis[J]. J Rare Dis, 2023, 2(1): 63-69. https://www.cnki.com.cn/Article/CJFDTOTAL-HJBI202301009.htm
|
| [23] |
Maurer M S, Schwartz J H, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J]. N Engl J Med, 2018, 379(11): 1007-1016.
|
| 1. |
刘玉文，张丽梅，王永丽，徐小梅，母亚丹，杨志杰，杨树婷，罗凤云. 老年多学科团队服务对共病伴营养不良老年患者的疗效分析. 昆明医科大学学报. 2024(12): 81-87 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: